Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Reddit to join S&P 500 index on Aug. 18, shares leap
- Should you chase this mini rally in gold? Citi weighs in
Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights
August 5, 2021 7:00 AM EDTGvoke® prescription volume up 32% versus prior quarter
Gvoke unit sales to wholesalers and other direct customers up 36% versus prior quarter
Gvoke quarterly net sales up 10% to $8.8 million versus prior quarter
Strong cash position of $116 million
FDA approved Gvoke 1mg shelf-life extension to 30 months
EIH program to move forward in early 2022 with a Phase 2 study in broader patient populations
Proposed acquisition of Strongbridge Biopharma plc on track to close early... More
